Evotec and Odyssey collaborate on AI-enabled R&D
Evotec and Odyssey have collaborated on AI-enabled R&D to accelerate the discovery of small molecule drug candidates for autoimmune and inflammatory diseases. The partnership combines Evotec's data-driven platforms with Odyssey's biological expertise to identify validated hit series. Evotec may receive milestone payments, though financial details are undisclosed.
A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.